(Q44083971)

29 November 2017

title

Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden (English)

1 reference

pneumococcal conjugate vaccine

29 November 2017

0 references

1 reference

based on heuristic

inferred from title

author

Ivar Sønbø Kristiansen

5

object named as

Ivar Sønbø Kristiansen

1 reference

29 November 2017

Annika Bergman

1

1 reference

29 November 2017

Jonas Hjelmgren

2

1 reference

29 November 2017

Ake Ortqvist

3

1 reference

29 November 2017

Torbjørn Wisløff

4

1 reference

29 November 2017

Liselotte Diaz Högberg

6

1 reference

29 November 2017

Kristina M S Persson

7

1 reference

29 November 2017

Ulf Persson

8

1 reference

29 November 2017

publication date

1 January 2008

1 reference

29 November 2017

1 reference

29 November 2017

volume

40

1 reference

29 November 2017

issue

9

1 reference

29 November 2017

page(s)

721-729

1 reference

The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F00365540802014872

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540802014872

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540802014872

Efficacy of a pneumococcal conjugate vaccine against acute otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540802014872

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540802014872

Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540802014872

The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540802014872

Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540802014872

Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540802014872

Is secretory otitis media a single disease entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540802014872

The effect of a pneumococcal conjugate vaccine on the risk of otitis media with effusion at 7 and 24 months of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540802014872

Capsular Types and Antibiotic Susceptibility of Invasive Streptococcus pneumoniae Among Children in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540802014872

National Institute for Clinical Excellence and its value judgments

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540802014872

Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination--a review (2002-2006).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365540802014872

10.1080/00365540802014872

21 January 2018

Identifiers

DOI

1 reference

29 November 2017

1 reference